ECT-001-CB (UM171-Expanded Cord Blood Transplant)

BIOLOGICAL3 trials

Sponsors

ExCellThera inc.

Conditions

Cord Blood TransplantHematopoietic Cell ProliferationHigh Risk Hematological MalignancyHigh Risk Myeloid MalignanciesSickle Cell DiseaseUmbilical Cord Blood

Phase 1

US Phase I Study of ECT-001-CB in Patients With Sickle-Cell Disease

WithdrawnNCT04594031

ExCellThera inc.Hematopoietic Cell Proliferation, Sickle Cell Disease, Umbilical Cord Blood

Start: 2021-07-13End: 2024-02-02Updated: 2022-07-05

US Study of ECT-001-CB in Pediatric and Young Adult Patients With High-Risk Myeloid Malignancies

CompletedNCT04990323

ExCellThera inc.Cord Blood Transplant, High Risk Myeloid Malignancies

Start: 2021-12-01End: 2025-12-31Updated: 2026-03-24

Phase 2

US Study of UM171-Expanded CB in Patients With High Risk Leukemia/Myelodysplasia

CompletedNCT04103879

ExCellThera inc.Cord Blood Transplant, High Risk Hematological Malignancy

Start: 2020-11-13End: 2026-02-28Updated: 2026-03-23